261 related articles for article (PubMed ID: 29911070)
1. Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.
Vander Ark A; Cao J; Li X
Front Oncol; 2018; 8():180. PubMed ID: 29911070
[TBL] [Abstract][Full Text] [Related]
2. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions.
Tucci M; Zichi C; Buttigliero C; Vignani F; Scagliotti GV; Di Maio M
Onco Targets Ther; 2018; 11():7353-7368. PubMed ID: 30425524
[TBL] [Abstract][Full Text] [Related]
3. Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.
Crona DJ; Whang YE
Cancers (Basel); 2017 Jun; 9(6):. PubMed ID: 28604629
[TBL] [Abstract][Full Text] [Related]
4. Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancer.
White RE; Bannister M; Day A; Bergom HE; Tan VM; Hwang J; Nguyen HD; Drake JM
bioRxiv; 2023 Apr; ():. PubMed ID: 37163118
[TBL] [Abstract][Full Text] [Related]
5. Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.
Armstrong CM; Gao AC
Asian J Urol; 2016 Oct; 3(4):185-194. PubMed ID: 28642838
[TBL] [Abstract][Full Text] [Related]
6. Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC.
White RE; Bannister M; Day A; Bergom HE; Tan VM; Hwang J; Dang Nguyen H; Drake JM
Front Oncol; 2023; 13():1210487. PubMed ID: 37456235
[TBL] [Abstract][Full Text] [Related]
7. Role of Androgen Receptor in Prostate Cancer: A Review.
Fujita K; Nonomura N
World J Mens Health; 2019 Sep; 37(3):288-295. PubMed ID: 30209899
[TBL] [Abstract][Full Text] [Related]
8. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer.
Rice MA; Malhotra SV; Stoyanova T
Front Oncol; 2019; 9():801. PubMed ID: 31555580
[TBL] [Abstract][Full Text] [Related]
9. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
Galletti G; Leach BI; Lam L; Tagawa ST
Cancer Treat Rev; 2017 Jun; 57():16-27. PubMed ID: 28527407
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
12. Resistance to Hormonal Therapy in Prostate Cancer.
Berruti A; Dalla Volta A
Handb Exp Pharmacol; 2018; 249():181-194. PubMed ID: 28353036
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.
Culig Z
Curr Mol Biol Rep; 2017; 3(4):230-235. PubMed ID: 29214142
[TBL] [Abstract][Full Text] [Related]
14. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
15. Splicing variants of androgen receptor in prostate cancer.
Zhang H; Zhan Y; Liu X; Qi Y; Zhang G; Sartor O; Dong Y
Am J Clin Exp Urol; 2013; 1(1):18-24. PubMed ID: 25374896
[TBL] [Abstract][Full Text] [Related]
16. [Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer].
Hupe MC; Offermann A; Perabo F; Chandhasin C; Perner S; Merseburger AS; Cronauer MV
Urologe A; 2018 Feb; 57(2):148-154. PubMed ID: 29147733
[TBL] [Abstract][Full Text] [Related]
17. Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells.
Khurana N; Chandra PK; Kim H; Abdel-Mageed AB; Mondal D; Sikka SC
Antioxidants (Basel); 2020 Jan; 9(1):. PubMed ID: 31940946
[TBL] [Abstract][Full Text] [Related]
18. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
[TBL] [Abstract][Full Text] [Related]
19. Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms.
Verma S; Prajapati KS; Kushwaha PP; Shuaib M; Kumar Singh A; Kumar S; Gupta S
Cancer Drug Resist; 2020; 3(4):742-761. PubMed ID: 35582225
[TBL] [Abstract][Full Text] [Related]
20. Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges.
Kita Y; Goto T; Akamatsu S; Yamasaki T; Inoue T; Ogawa O; Kobayashi T
Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30248934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
